

## **STELARA (USTEKINUMAB) ORDER SET**

A Carelon Company

P: 877.365.5566 | F: 855.889.2946

PATIENT INF	ORMATION:	Fax completed form, ir	nsurance information, and clin	ical documentation to 855.889.2946
Patient Name:			DOB:	Phone:
			Next Treatment D	
MEDICAL INF	ORMATION			
Patient weight: _	lbs. (required	I) Allergies:		
THERAPY OR	DER			
Stelara (adult do Patients 12 weeks	sing): weighing < 100kg (22 s x 1 year weighing > 100kg (22	20 lbs.), 45mg subQ		er, followed by 45mg every r, followed by 90mg every
□ Other:				
Stelara (adult do	sing): n: □ ≤55kg (<121 lbs. □ >55kg to 85kg (	) 260mg IV over 1 h	90mg IV over 1 hour x 1	
Maintenance:	90mg subQ 8 w for a total of 6 i		usion and then refill eve	ry 8 weeks for 1 year
Lab Orders:			Lab Frequency:	
				n 🛛 Referring Provider
Other orders:				_
Home IV Biologic A • Epinephrine: • Diphenhydra • NS 0.9% 100 Home biologic inje	Ana-kit Orders (adult):	en 0.3mg or compounc mg orally OR IV (adult col PRN (adult)	led syringe IM or subQ; may	y repeat in 5-10 minutes x1
	order or institutional pro 20mL pre/post infusion		sing Ana-kit /mL or 100U/mL per proto	col as indicated PRN
PROVIDER IN	FORMATION			
agent in dealing with medic Provider Name: _ Provider NPI:	al and prescription insurance com	panies, and to select the preferre Signature Fax	d site of care for the patient.	uthorization and specialty pharmacy designated Date: Date:
PREFERRED LOCATION				
City:	State:		/iew our locations here:	
		PARAGONHEALTH	ICARE.COM	

IMPORTANT NOTICE: This fax is intended to be delivered only to the named address and contains material that is confidential, privileged property, or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute, or copy this fax. Please notify the sender immediately and destroy all copies if you have received this document in error.





## COMPREHENSIVE SUPPORT FOR STELARA (USTEKINUMAB) THERAPY

A Carelon Company

PATIENT INFORMATION:	
Patient Name:	DOB:
<b>REQUIRED DOCUMENTATION FOR REFERRAL PROCESSING &amp;</b>	<b>INSURANCE APPROVA</b>
Include <u>signed</u> and <u>completed</u> order (MD/prescriber to compl	lete page 1)
igta Include patient demographic information and insurance inform	mation
Include patient's medication list	
Supporting clinical notes to include any past tried and/or faile penefits, or contraindications to conventional therapy	ed therapies, intolerance,
Has the patient had a documented contraindication/intole DMARD, NSAID, or conventional therapy (i.e., MTX, 6-MP)? If yes, which drug(s)?	□Yes □No
□ Does the patient have a contraindication/intolerance or fai biologic (i.e., Humira, Otezla, Stelara, Cimzia)? □ Yes □ No If yes, which drug(s)?	)
$\Box$ If psoriasis diagnosis, percent of body surface (BSA) involv	/ed: %
$\Box$ If psoriasis diagnosis, Psoriasis Area and Severity Index (PA	ASI) score:
Include labs and/or test results to support diagnosis	
If applicable - Last known biological therapy: If patient is switching to biologic therapies, out period of weeks prior to starting Stelara.	_ and last date received: please perform a wash-
Other medical necessity:	
REQUIRED PRE-SCREENING	
TR coreening test (completed within 12 menths if a new star	

## J TB screening test (completed within 12 months if a new start) - attach results D Positive D Negative

\*If TB results are positive - please provide documentation of treatment or medical clearance, and a negative CXR (TB+)

Paragon Healthcare will complete insurance verification and submit all required documentation for approval to the patient's insurance company for eligibility. Our team will notify you if any additional information is required. We will review financial responsibility with the patient and refer him/her to any available co-pay assistance as needed. Thank you for the referral.

## Please fax all information to (855) 889-2946 or call (877) 365-5566 for assistance

PARAGONHEALTHCARE.COM

IMPORTANT NOTICE: This fax is intended to be delivered only to the named address and contains material that is confidential, privileged property, or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute, or copy this fax. Please notify the sender immediately and destroy all copies if you have received this document in error.